Triple Test Screening for Down Syndrome: an Egyptian-tailored Study

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2014 Oct 21

PMID 25330176

Citations 1

Authors

Hazem S Abou-Youssef

Manal M Kamal

Dina A Mehaney

Affiliations

Soon will be listed here.

Abstract

Background: The incidence of Down syndrome (DS) in Egypt varies between 1:555 and 1:770 and its screening by triple test is becoming increasingly popular nowadays. Results, however, seem inaccurate due to the lack of Egyptian-specific information needed for risk calculation and a clear policy for programme implementation. Our study aimed at calculation and validation of the triple marker medians used in screening Egyptian females as well as to recommend programme conventions to unify screening in this country.

Methods: The study was conducted on 668 Egyptian women, in weeks 15-20 of pregnancy as proven by sonar. Chorionic gonadotropin (CG), α-fetoprotein (AFP) and unconjugated oestriol (uE3) were measured on Siemens Immulite analyzer. Medians of the three parameters were calculated, regressed against gestational age (GA) and weighted by the number of participants/week. Equations were derived to adjust each parameter to the maternal weight and were centered on the median Egyptian weight. Prisca software was fed with the above data, multiples-of-median (MoM) and DS risks were calculated and the screening performance was evaluated at a mid-trimester risk cutoff of 1:270.

Results: Log-linear [AFP/uE3 = 10(A+B*GA)] and exponential equations [CG = A*e (B*GA)] were derived and the regressed medians were found to follow similar patterns to other Asian and Western medians. Oestriol was always lowest (even halved) while CG and AFP were intermediate. A linear reciprocal model best fitted weight distribution among Egyptians and successfully adjusted each parameter to a weight of 78.2 kg. Epidemiological monitoring of these recommendations revealed satisfactory performance in terms of 6.7% initial positive rate and 1.00 grand MoM.

Conclusions: Adoption of the above recommendations is hoped to pave the way to a successful DS screening programme tailored to Egyptian peculiarities.

Citing Articles

The prevalence of hearing impairment in infants and children with down syndrome a cross sectional study in a Tertiary Care Center.

Yahia S, Metawea M, Megahed A, ELshawaf W, Wahba Y, Mahmoud R Sci Rep. 2025; 15(1):7570.

PMID: 40038479 PMC: 11880191. DOI: 10.1038/s41598-025-90500-7.

Association between FTO gene polymorphism and obesity in down syndrome children.

Mourad S, El-Farahaty R, Atwa M, Yahia S, El-Gilany A, Elzeiny A Eur J Pediatr. 2024; 184(1):95.

PMID: 39706986 PMC: 11662052. DOI: 10.1007/s00431-024-05909-5.

References

Palomaki G, Bradley L, McDowell G . Technical standards and guidelines: prenatal screening for Down syndrome. Genet Med. 2005; 7(5):344-54. DOI: 10.1097/01.gim.0000167808.96439.f3. View

MacRae A, Gardner H, Allen L, Tokmakejian S, Lepage N . Outcome validation of the Beckman Coulter access analyzer in a second-trimester Down syndrome serum screening application. Clin Chem. 2003; 49(1):69-76. DOI: 10.1373/49.1.69. View

Lambert-Messerlian G, Eklund E, Malone F, Palomaki G, Canick J, DAlton M . Stability of first- and second-trimester serum markers after storage and shipment. Prenat Diagn. 2005; 26(1):17-21. DOI: 10.1002/pd.1326. View

Snijders R, Sundberg K, Holzgreve W, Henry G, Nicolaides K . Maternal age- and gestation-specific risk for trisomy 21. Ultrasound Obstet Gynecol. 1999; 13(3):167-70. DOI: 10.1046/j.1469-0705.1999.13030167.x. View

Hafez M, Zedan M, Eisa M . Demographic trends of Down's syndrome in Egypt. Hum Biol. 1984; 56(4):703-12. View

Palomaki G, Neveux L, Haddow J . Can reliable Down's syndrome detection rates be determined from prenatal screening intervention trials?. J Med Screen. 1996; 3(1):12-7. DOI: 10.1177/096914139600300105. View

Benn P, Borgida A, Horne D, Briganti S, Collins R, Rodis J . Down syndrome and neural tube defect screening: the value of using gestational age by ultrasonography. Am J Obstet Gynecol. 1997; 176(5):1056-61. DOI: 10.1016/s0002-9378(97)70402-2. View

Wald N, Hackshaw A, George L . Assay precision of serum alpha fetoprotein in antenatal screening for neural tube defects and Down's syndrome. J Med Screen. 2000; 7(2):74-7. DOI: 10.1136/jms.7.2.74. View

Bishop J, Dunstan F, Nix B, Reynolds T . The effects of gestation dating on the calculation of patient specific risks in Down's syndrome screening. Ann Clin Biochem. 1995; 32 ( Pt 5):464-77. DOI: 10.1177/000456329503200506. View

10.

Wang Y, Luo J, Zhu M, Liu L, Ma X . Second-trimester double or triple screening for Down syndrome: a comparison of Chinese and Caucasian populations. Int J Gynaecol Obstet. 2006; 94(1):67-72. DOI: 10.1016/j.ijgo.2006.04.030. View

11.

. ACOG Practice Bulletin No. 77: screening for fetal chromosomal abnormalities. Obstet Gynecol. 2007; 109(1):217-27. DOI: 10.1097/00006250-200701000-00054. View

12.

Reynolds T, Penney M . The mathematical basis of multivariate risk screening: with special reference to screening for Down's syndrome associated pregnancy. Ann Clin Biochem. 1990; 27 ( Pt 5):452-8. DOI: 10.1177/000456329002700506. View

13.

Neveux L, Palomaki G, Larrivee D, Knight G, Haddow J . Refinements in managing maternal weight adjustment for interpreting prenatal screening results. Prenat Diagn. 1996; 16(12):1115-9. DOI: 10.1002/(SICI)1097-0223(199612)16:12<1115::AID-PD3>3.0.CO;2-6. View

14.

Kwon J, Park I, Park Y, Lee Y, Lee G, Shin J . Korean-specific parameter models for calculating the risk of Down syndrome in the second trimester of pregnancy. J Korean Med Sci. 2011; 26(12):1619-24. PMC: 3230023. DOI: 10.3346/jkms.2011.26.12.1619. View

15.

OBrien J, Dvorin E, DRUGAN A, Johnson M, Yaron Y, Evans M . Race-ethnicity-specific variation in multiple-marker biochemical screening: alpha-fetoprotein, hCG, and estriol. Obstet Gynecol. 1997; 89(3):355-8. DOI: 10.1016/S0029-7844(96)00524-8. View

16.

Cuckle H . Improved parameters for risk estimation in Down's syndrome screening. Prenat Diagn. 1995; 15(11):1057-65. DOI: 10.1002/pd.1970151111. View

17.

Wald N, Cuckle H, Densem J, Kennard A, Smith D . Maternal serum screening for Down's syndrome: the effect of routine ultrasound scan determination of gestational age and adjustment for maternal weight. Br J Obstet Gynaecol. 1992; 99(2):144-9. DOI: 10.1111/j.1471-0528.1992.tb14474.x. View

18.

Reynolds T, Ellis A, Jones R . Down's syndrome risk estimates demonstrate considerable heterogeneity despite homogeneity of input. Ann Clin Biochem. 2004; 41(Pt 6):464-8. DOI: 10.1258/0004563042466901. View

19.

Vranken G, Reynolds T, Van Nueten J . Medians for second-trimester maternal serum markers: geographical differences and variation caused by median multiples-of-median equations. J Clin Pathol. 2006; 59(6):639-44. PMC: 1860408. DOI: 10.1136/jcp.2005.034272. View

20.

Benn P . Advances in prenatal screening for Down syndrome: I. general principles and second trimester testing. Clin Chim Acta. 2002; 323(1-2):1-16. DOI: 10.1016/s0009-8981(02)00186-9. View